is imperative for the development of personalized therapeutic approaches for the diagnosis, prognosis, and treatment of PCa.
MicroRNAs (miRNAs, or miRs) consist of a series of short (18-22 nucleotides) , noncoding, single-stranded RNA molecules. miRNAs can selectively bind to the 3'untranslated region (3' UTR) of downstream target mRNAs, promoting their degradation. miRNAs can also impede biosynthesis of specific proteins, and subsequently regulate multiple physiological processes. 5, 6 Also, accumulating evidence shows that dysregulation of miRNAs can have tumor-suppressive or oncogenic effects in the development and progression of several cancers, including prostate cancer, by regulating tumor growth, metastasis, and epithelial to mesenchymal transition (EMT). [7] [8] [9] It has been reported that miR-133a and miR-150 inhibit the growth of metastatic prostate cancer by regulating MAP3K12 expression or by activating PI3K/ AKT signaling. Oncogenic factors, such as miR-203, miR-410, and miR-34a, have been identified as carcinogenic factors that promote proliferation of PCa cells. [10] [11] [12] Notably, miR-200a, a member of the miR-200 family, has been shown to participate in several biological processes that regulate the progression of tumors. [13] [14] [15] [16] [17] [18] However, the role of miR-200a in prostate cancer development and progression has not been investigated. After using miRNA chip expression spectrum detection technology and analyzing the miRNA expression profile of prostate cancer patients in the Memorial Sloan Kettering Cancer Center (MSKCC) database, we found that there were differences in the expression of miR-200a in androgen-dependent prostate cancer (ADPC) tissues and castration-resistant prostate cancer (CRPC) tissues. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) confirmed that miR-200a was significantly lower in cancer tissues from CRPC patients. Statistical analysis also revealed that miR-200a is an independent risk factor for the prognosis of prostate cancer patients.
Therefore, we conducted a series of cellular functional experiments by overexpressing miR-200a in prostate cancer cells and observing the effect on proliferation, invasion, colony formation, and apoptosis of prostate cancer cells. We also found that bromodomain containing protein 4 (BRD4) is a potential downstream target gene of miR-200a, and the association between miR-200a and BRD4 was verified by western blot analysis. Therefore, the results of our study suggest that miR-200a acts as an anti-oncogenic factor to inhibit the progression of CRPC by suppressing BRD4-mediated androgen receptor (AR) signaling.
| MATERIALS AND METHODS

| Patients and tissue samples
Twenty tissue samples were obtained from PCa patients during surgery at the Affliated Zhongda Hospital of Southeast University (Nanjing, China) including 10 ADPC tissues after early radical prostateectomy and 10 tissues from CRPC patients who suffered from transurethral resection of the prostate (TURP). The age of the patients ranged from 64 to 79 years (average age: 66 years). Among the ADPC patients, eight patients were diagnosed with ADPC stage II and two patients with stage III; seven patients had Gleason score <7; two patients with Gleason score =7, and one patient with Gleason score >7. Castration-resistant prostate cancer specimens are derived from 10 patients with CRPC, of whom the serum prostate-specifc antigen (PSA) levels continued to increase maxima during androgen-deprivation therapy. The clinical stage of patients with CRPC were all in stage IV and all patients with a Gleason score >8. The clinical samples were obtained during TURP because of urinary retention. For each specimen, a portion of tumor tissue was confirmed as staining for PSA and only the samples with >60% tumor involvements were included in the study. The specimens were routinely fixed with polyformaldehyde and embedded with paraffin wax for routine clinical pathological analysis and subsequent experimental research. Informed consent was obtained from the included patients. All procedures performed in this study were approved by the Ethics Committee of the Affliated Zhongda Hospital of Southeast University.
| Cell culture
The LNCaP and C4-2B PCa cell lines were obtained from the Urological Institute of the Affliated Zhongda Hospital of Southeast University. LNCaP cells were maintained in the medium of RPMI-1640 (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum and antibiotics; C4-2B cells were cultured in DMEM/12 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum and antibiotics. All cell lines were maintained at 37°C in a humidified chamber supplemented with 5% CO2.
| Oligonucleotide and plasmid transfection
Based on miRBase database, miR-200a mimic, negative control of miRNA (miR-NC), anti-miR-200a oligos (anti-miR200a), and negative control anti-miRNA (anti-NC) were obtained from GenePharma (Shanghai, China). Short interfering RNA(siRNA) against BRD4 (si-BRD4) and negative control siRNA with nonspecific sequences (si-NC) were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For cell transfection, LNCaP and C4-2B cells were seeded in 6-well plates and the transfection was performed using Lipofectamine 3000 (Thermo Fisher) following the manufacturer's protocol. At 48 hours after transfection, the cells were used in the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide, Thiazolyl Blue Tetrazolium Bromide), transwell, colony formation, and western blotting assays. 
| Stable transfection
Reverse complement sequence of miR-200a was synthesized and inserted into the AgeI/EcoR1 site of GV209 vector (GeneChem, Shanghai, China) to construct a vector expressing miR-200a named LV-miR-200a. The GFP vector was used for control. The viruses were used to infect C4-2B cells in the presence of polybrene. The effciency of miR-200a overexpression was determined by fluorescence microscopy.
| Colony formation assay
Cell proliferation was evaluated based on colony numbers via the colony formation assay. In brief, LNCaP and C4-2B cells were seeded in 6-well plates at a density of 500 cells per well and incubated for 12 days at 37°C in 5% CO2. Next, the cells were washed thrice with phosphate buffer solution(PBS), fxed with methanol for 15 minutes, and stained with 300µL of 0.1% crystal violet for 20 minutes at room temperature. Colonies containing more than 50 cells were counted by the ImageJ 2X software.
| Transwell assays
For invasion assays, transfected-PCa cells were diluted to the final concentration of 5.0 × 10 6 /mL. Postdiluted PCa cells in 100 μl serum-free medium were seeded in the top chamber of 24-well transwell units which were precoated with Matrigel (BD Pharmingen, Franklin Lake, NJ, USA) while the bottom chambers were filled with RPMI-1640 containing 10% FBS. The top chamber was taken out after placing the chamber in the cell incubator for 24 hours at 37°C. Cells in the top chambers were removed and cells that invaded into the bottom chambers were fxed with methanol and stained with 0.2% crystal violet. The cells that migrated to the bottom chamber of the membrane were counted and photographed microscopically. 
| Cell proliferation assay
| RNA extraction and quantitative realtime PCR (qRT-PCR)
Total RNA was extracted from PCa cells with TRIzol (Invitrogen™, Thermo Fisher Scientific) following the manufacturer's protocol. cDNA synthesis were performed using total RNA and the PrimeScript RT reagent (Takara, Kusatsu, Japan), and qRT-PCR was performed on ABI 7300 system (Applied Biosystems, Shanghai, China). miRNA were normalized using GAPDH and the expression of U6 as endogenous controls. PCR results were analyzed using OpticonMonitor3 software (BioRad, Irvine, CA) and relative gene expression was calculated by the 2 −ΔΔCt method. The expression of 2 −ΔΔCt was the ratio of gene expression between experimental group and control group. Experiments were conducted for three times to obtain the average value.
| Western blot analysis
The total proteins were extracted from PCa cells lysed in RIPA buffer according to the manufacturer's instructions and quantified by BCA assay (Beyotime, Shanghai, China).
The protein were analyzed by 10% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and the gels were transferred onto a polyvinylidene fluoride (PVDF) membrane blocked with 5% nonfat dried milk in TBST for 1 hour. Afterward, the PVDF membranes were incubated with specifc primary antibodies overnight at 4°C. After washing three times with TBST buffer, the membranes were then incubated with 1:2000 secondary antibodies for 1 hour and the bands were visualized by an enhanced chemiluminescence (ECL, Millipore, USA). The primary antibodies used in the present study included anti-BRD4 (1:1000, Abcam, USA), anti-AR (1:200, Abcam, USA), anti-AR-V7 antibody (1:1000, Abcam, USA), and anti-C-myc antibody (1:1000, Abcam, USA). GAPDH was used as an internal control.
| In vivo tumorigenicity assay
Six-week old BALB/C nu/nu female mice were purchased from the Shanghai SLAC Laboratory Animals. All animal experiments were approved by the Institutional Animal Care and conducted according to the National Institute of Health Guide for the Care. The availability of laboratory animals was approved by the ethics committee of the Affliated Zhongda Hospital of Southeast University. C4-2B (4 × 10 6 ) cells transfected with LVmiR-200a were injected subcutaneously into the oxter flank of nude mice for a 7-day implantation time during which tumor size was measured at 2-day interval and tumor volumes were calculated as the follows: V (mm3) = width (mm2) × length (mm)/2. The mice were sacrificed and tumors were dissected and weighed at the end of the experiments.
| In vivo metastasis assay and bioluminescence imaging analysis of lung metastasis
C4-2B (2 × 10 6 ) cells transfected with LV-miR-200a or LV-NC for 48 hour were washed and suspended in 0.1 ml PBS and subsequently injected into the lateral tail vein. The injected mice were anesthetized immediately using isoflurance and injected with 150 mg/kg of D-luciferin (15 mg/ ml in PBS) intraperitoneally to demonstrate lung location of PCa cells. After a 7-week monitoring time, mice were anesthetized and injected with D-luciferin for 10 minutes as the first time. The nude mice were imaged with a highly sensitive camera in a light-tight specimen chamber (IVIS200, Xenogen). Living Image software (Xenogen) was conducted to acquire and quantify bioluminescence signals. Bioluminescence imaging was correlated with lung tumor volumes estimated using caliper measurements and a standard formula: 1/6 × width × length × depth.
| In situ hybridization (ISH) and immunohistochemical staining (IHC)
MicroRNA in situ hybridization (ISH) Buffer and Controls kit (Exiqon, Vedbaek, Denmark) were used for ISH. The double (5′-3′) digoxigenin (DIG)-labeled miR-200a probe and U6 probe were purchased from Boster (Wuhan, China) and ISH was conducted according to the manufacturer's protocol of the microRNA ISH Optimization Kit (Boster, Wuhan, China). The expression of BRD4, Ki-67, and caspase-3 were detected by immunohistochemistry in the specimens which were fxed in 10% neutral-buffered formalin and subsequently embedded in paraffn. After a brief proteolytic digestion and peroxidase blocking of the tissue slides which were cut to a thickness of 4 µm previously, the slides were incubated overnight at 4°C with the anti-BRD4 (1:1000, Abcam, USA), anti-ki67, and anti-caspase-3 (All 1:100, Boster, China). In situ hybridization and IHC were scored in a semiquantitative manner. The scoring system was conducted as follows: 0 (<5%), 1 (5%-30%), 2 (31%-70%), and 3 (≥71%). Additionally, the staining intensity was stratified as follows: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Based on the intensity score, the percentage of positive cells were multiplied to obtain the final immunoreactivity scores (IRS) for Ki-67. Apoptosis ability in the tumor xenografts was also determined from the number of Caspase-3-positive cells.
| Statistical analysis
MiR-200a expression with clinical patient data was downloaded from the MSKCC (GSE21032) database (http:// www.mskcc.org). Statistical analyses were performed with the Statistical Package of the Social Sciences software version 22.0 (SPSS, Inc, Armonk, NY, USA). Student's t test and one-way ANOVA analysis were used to compare the significance of two groups. The Kaplan-Meier method was performed to generate survival curves and Cox regression analysis was used for univariate and multivariate analyses. All experiments above were repeated three times and differences among groups in in vitro or in vivo studies were utilized as two-tailed Student's t test. Data are presented as means and standard deviation (SD). A P-value of <0.05 was considered statistically signifcant.
| RESULTS
| miR-200a is specifically downregulated in CRPC and inversely associated with progression and poor prognosis of CRPC
In our previous microarray analysis, we totally detected 1646 miRNAs expressed in prostate cancer tissue. 19 Among them, we found that 370 miRNAs were differentially expressed between ADPC and CRPC. From the microarray dataset, we discovered 167 miRNAs were downregulated in CRPC. As shown in Table 1 , miRNAs including miR-200a, miR-205, miR-1248, miR-26a, and miR-130a, were significantly decreased in CRPC in comparison to ADPC, among which miR-200a was initially selected for further study ( Figure 1A ). To validate whether the above conclusion is applicable to large number of clinical PCa samples, we conducted the reanalysis of the RNA sequencing data acquired from MSKCC PCa database (GSE21032). It is well-known that biochemical recurrence of PCa refers to two consecutive serum PSA levels >0.2 μg/L after radical surgery or radiation treatment of prostate cancer. Therefore, the prostate cancer patient dataset used in this study was divided into miR- expression and the time for biochemical recurrence after radical surgery of prostate cancer. The results showed that the biochemical relapse-free survival (RFS) of patients in the miR-200a-low group was significantly shorter than that of the miR-200a-high group, P < 0.0001( Figure 1B) . In order to clarify whether miR-200a expression was associated with the outcome of PCa patients, we performed Cox regression analysis to identify variables of potential prognostic significance.
The results suggested that miR-200a expression (P = 0.032), Gleason score (GS) (P = 0.001), prostate-specific antigen levels (PSA) (P = 0.002), and lymph node invasion (LNI) (P = 0.044) were independent prognostic factors for biochemical relapse-free survival in patients with PCa. However, other factors such as seminal vesicle invasion (SVI), surgical margins (SMS), extracapsular extension (ECE), and pathological stage (pStage) were not predictive of prognosis ( Table 2 ). All results from MSKCC database implied that miR-200a-low represents a poor prognostic factor of CRPC patient. Since miR-200a has been reported to play the critical roles in multiple other malignancies, there is no report of miR-200a involved in human CRPC. To verify the microarray results, we performed ISH staining on 10 ADPC tissues and 10 CRPC tissues with miR-200a probe and we observed that miR-200a expression was lower expression in CRPC compared with that in ADPC ( Figure 1C ). These data showed that miR-200a may function as a tumor suppressor during PCa progression, and its expression level is associated with the transformation of ADPC to CRPC.
| miR-200a inhibits PCa cell proliferation, invasion, and facilitates apoptosis in vitro
Quantitative real-time PCR results showed that miR-200a expression levels were significantly downregulated in C4-2B cell lines in comparison to LNCaP cells ( Figure 1D 
| Upregulation of miR-200a suppresses the formation of prostate cancer xenograft tumors in vivo
After subcutaneous injection of C4-2B cells that transfected with preconstructed lentiviral expression vector (LV-miR200a) and LV-NC (control) into nude mice ( Figure 3A) , we further determined the tumor-suppressive effects of miR-200a. As shown in Figure 3B ,C,D,E, upregulation of miR-200a significantly suppressed tumor growth as verified by comparatively smaller tumor sizes and weights. We also showed by western blot analysis that miR-200a-overexpressing C4-2B xenografts expressed higher levels of BRD4 protein in comparison to control xenografts ( Figure  3F ). Proliferation and apoptosis of the tumor xenografts were subsequently analyzed by immunohistochemical staining of the proliferation marker Ki67 and the apoptosis marker activated caspase Figure 5E ). Therefore, our data strongly suggest that BRD4 is functionally involved in miR-200a-mediated suppression in PCa cells. 
| DISCUSSION
miRNAs have been extensively studied over the past two decades, and their involvement in virtually all cellular processes by regulating gene expression has been well demonstrated. Therefore, the aberrant expression of these short nucleotide sequences can serve tumor-suppressive or protumorigenic roles in many malignant tumors, including prostate cancer. 20 In this study, we investigated the molecular function of miR200a and identified novel gene targets of miR-200a in PCa. We found that upregulation of miR-200a significantly inhibited cell proliferation and migration, and promoted apoptosis of PCa cell lines. Moreover, BRD4 was identified as a novel gene target of miR-200a, and a mediator of miR-200a oncogenic activity through AR signaling. The first report concerning miR-200a showed its high expression in olfactory tissues. 21 Subsequently, its involvement in human disease was demonstrated with downregulated miR-200a involvement in cellular biological processes, including cell proliferation, and apoptosis. Moreover, it has been reported that miR-200a is related to the occurrence and development of endometrial cancer, breast cancer, and esophageal cancer by targeting genes, such as PTEN, EPHA2, and CRMP-1. 15, 22, 23 In prostate cancer, it has been reported that miR-200b/a inhibits PCa cell growth and invasion by downregulating ERG expression. 24 Bian et al demonstrated that miR-200a is involved in the oncogenesis and migration of CRPC. 25 Another study showed that miR-200a is overexpressed in prostate cancer and may serve as a predictive biomarker of RFS. 26 miRNAs, such as miR-125b, miR-146a, miR-744, and miR-34a, have also been shown to function either as an oncogene or as a tumor suppressor in PCa. 12, [27] [28] [29] However, the underlying molecular mechanisms of the biological functions of miR-200a remain unknown.
In our current study, we discovered that miR-200a levels are lower in human CRPC specimens than in human ADPC samples. We also demonstrated that miR-200a can suppress cell proliferation, colony formation, and invasion of CRPC in vitro, as well as enhance xenograft tumor growth in vivo. Therefore, we surmised that miR-200a behaves as an anti-oncogenic factor in the progression of ADPC to CRPC.
The differential target genes regulated by miR-200a are possibly responsible for the protumorigenic effects of miR-200a. We used a luciferase reporter assay to demonstrate that BRD4 is a target gene of miR-200a. BRD4, a member of The relative firefly luciferase activity was normalized and measured 48 h after transfection. Each bar represents the mean ± SD of three independent experiments. *P < 0.05. E, Western blot assay showed the comparison of relevant protein expression levels. GAPDH was used as an internal control the BET (Bromodomain and extraterminal domain) family, is a transcriptional regulator in mitotic cells and plays a crucial role in cancers. BET proteins bind to the chromosome and regulated gene expression by recognizing the acetyl-lysine residues of histones or by interacting with other transcription factors, such as members of the transcription elongation complex. 30 Aside from its essential role in normal cell cycle, differentiation, and development, BRD4 has also been demonstrated to participate in various biological processes in tumor cells, including cell invasion, migration, proliferation, and EMT, by acting as an oncogene. 31 A growing body of evidence has documented that BRD4 can serve as a prognostic factor of bladder urinary epithelial carcinoma, serves as a treatment target for acute myelogenous leukemia, and predicts the survival of breast cancer patients. [32] [33] [34] However, the molecular role and clinical relevance of BRD4 in PCa remains unclear. Here, we detected that BRD4 was upregulated in PCa tissues. In vitro assays indicated that BRD4 downregulation inhibited the proliferation of PCa tumor cells. Additionally, xenograft tumor models further showed that the knockdown of BRD4 significantly suppressed tumor growth in vivo. These findings demonstrated that BRD4 functions as a protumorigenic factor in PCa progression. Previous studies have demonstrated that BRD4 can promote the transcriptional activities of oncogenic factors in prostate cancer by physically interacting with the N-terminal domain of androgen receptor (AR), which is a crucial element of the AR signaling pathway. The progression of ADPC to CRPC is characterized by the abnormal activation of AR signaling and overexpression of AR target genes, such as PSA, the expression of which is tightly association with PCa progression. To further verify the relationship between miR-200a Studies have demonstrated that BET inhibitors (BETi) such as JQ1 can competitively bind to the amino terminal bromodomains of BRD4, leading to the replacement of BRD4 from active chromatin. As a result, RNA polymerase II is removed from active chromatin, ultimately altering the expression of target genes, such as FOS, Jun, and c-myc, which are significantly involved in AR signaling in CRPC. 35, 36 Additionally, it has been reported that BETi can directly modulate c-myc gene expression and subsequently abrogate AR signaling and the progression of CRPC. 36, 37 Therefore, inhibiting the positive modulator of BRD4 represents a novel strategy to control the aberrant activation of AR signaling. Until now, a number of bromodomain inhibitors, including JQ1 and I-BET, have been developed and have shown promising outcomes in preclinical and early clinical trials. 36, 38 Our study has uncovered a novel anti-tumorigenic role for miR-200a in the progression of CRPC, which is mediated by disrupting BRD4/AR signaling. In summary, this study characterized the role of miR-200a and its anti-tumorigenic effect of attenuating the progression of ADPC to CRPC. Most importantly, we identified the functional regulation of BRD4-AR signaling by miR-200a, which associates with patient outcomes in aggressive prostate cancer. Therefore, the downstream gene regulation by miR-200a/BRD4 should be investigated further to foster the development of novel anticancer therapies for patients with CRPC.
